Norway, March 9 -- Zelluna, a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a collaboration with Etcembly Ltd, a biotechnology company applying advanced machine learning to T cell receptor (TCR) discovery and engineering.Highlights: * AI-enabled collaboration to engineer KKLC1-targeting TCRs for Zelluna's TCR-NK platform * Builds on successful engineering of MAGE-A4 TCR underpinning ZI-MA4-1, approved for clinical testing in February 2026 * Expands pipeline with validated solid tumour antigen expressed across multiple difficult-to-treat cancers * AI-guided in silico engineering to enhance specificity, potency and development effi...